AQR Capital Management LLC Has $560,000 Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

AQR Capital Management LLC lessened its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 48.8% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 27,273 shares of the company’s stock after selling 25,943 shares during the quarter. AQR Capital Management LLC’s holdings in Syndax Pharmaceuticals were worth $560,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Sei Investments Co. boosted its position in shares of Syndax Pharmaceuticals by 2.5% in the first quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after buying an additional 991 shares during the period. California State Teachers Retirement System boosted its position in Syndax Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock valued at $1,822,000 after purchasing an additional 1,150 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in Syndax Pharmaceuticals by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock valued at $187,000 after purchasing an additional 1,312 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its position in Syndax Pharmaceuticals by 28.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock valued at $171,000 after purchasing an additional 1,587 shares during the last quarter. Finally, nVerses Capital LLC acquired a new stake in Syndax Pharmaceuticals during the second quarter valued at $33,000.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock opened at $19.82 on Tuesday. The business’s 50-day simple moving average is $19.33 and its 200-day simple moving average is $20.69. The firm has a market capitalization of $1.69 billion, a PE ratio of -5.86 and a beta of 0.91. Syndax Pharmaceuticals, Inc. has a 52 week low of $11.22 and a 52 week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.11. The firm had revenue of $3.50 million for the quarter. During the same quarter last year, the company earned ($0.64) EPS. The firm’s revenue for the quarter was up 3499999990.0% on a year-over-year basis. Research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.66 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SNDX. JPMorgan Chase & Co. reduced their price objective on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Citigroup lifted their price objective on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Stifel Nicolaus lifted their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday. HC Wainwright boosted their price target on Syndax Pharmaceuticals from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Finally, Bank of America boosted their price target on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $35.78.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).